PHIOGEN has been recognized as one of the Top 10 Most Promising Life Science Companies at the 14th Annual Texas Life Science Forum, Texas’s premier gathering of biotech, medtech, and health-innovation leaders. Selected by a panel of investors and industry experts, PHIOGEN stood out among dozens of presenting ventures spanning therapeutics, devices, and digital health.…
(BOSTON: August 26, 2025) – Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) has awarded PHIOGEN US$1.1M to evaluate PHI-BI-01, its novel, dual-action therapeutic designed to treat and prevent extraintestinal pathogenic Escherichia coli (ExPEC) bloodstream infections, particularly those caused by multidrug-resistant strains.This next-generation phage-based project aims to reduce mortality and recurrence in patients suffering from life-threatening bacterial sepsis by combining immediate bacterial killing with long-term immune protection from subsequent infections.…
PHIOGEN, a biotech company developing live biotherapeutic products (LBPs) for drug-resistant and recurrent bacterial infections, is collaborating with patient research and advocacy organization Live UTI Free (LUF) to empower their clinical development efforts. The new alliance will advance the optimization of bacteriophage therapeutics to treat recurrent UTIs (urinary tract infections) through education and by connecting…
Biotech startup PHIOGEN earned the top spot for its diversity, equity and inclusivity (DEI) efforts, outcompeting 45 companies shortlisted for the Best Inclusivity award at the 16th Annual SXSW Award Ceremony. PHIOGEN attended the widely renowned conference after being selected out of 670 companies as a finalist in the Food, Nutrition & Health category at…
PHIOGEN, a pioneering startup developing next-generation bacteriophage-based therapeutics, has appointed Dr. Mayukh Das as Chief Operations Officer (COO). Dr. Das joins PHIOGEN from Johnson & Johnson Innovative Medicine where he served as Associate Scientific Director of Phage Microbiology and brings with him more than 19 years’ experience managing medical research and pharmaceutical product development. Dr.…
Newly-launched biotech venture, PHIOGEN, received an enthusiastic reception at the 6th World Conference on Targeting Phage Therapy, where it was recognized by organizers with the ‘Best Scientific Innovation Award’. The company, which is a spin-off from Baylor College of Medicine and was born out of innovation from the team at TAILOR Labs, made its debut…
Ambitious new biotech venture PHIOGEN has developed a world-first technology platform that mobilizes the natural power of bacteriophages to tackle critical and life-threatening infections, marking a significant medical breakthrough for countering the global threat of antimicrobial resistance. The company will make its debut at the 6th World Congress on Targeting Phage Therapy in Paris, June…
PHIOGEN™ is a trademark of PHIOGEN INC. PHIOGEN is an innovative biotech company housed in the Texas Medical Center’s Innovation Hub and is committed to using proven technology to deliver patient-ready bacteriophage products to tackle the most deadly and serious bacterial infections facing our world. PHIOGEN’s world-class patented process has received early proof of concept validation through several in vivo studies as well as use in patients under FDA approved compassionate use cases.
![009-01-Melissa-Kramer-[L]-and-Amanda-Burkardt-[R]](https://gk.news/phiogen/wp-content/uploads/sites/64/2024/11/009-01-Melissa-Kramer-L-and-Amanda-Burkardt-R-400x235.jpg)
